AU2015247382B2 - Beta-lactamases with improved properties for therapy - Google Patents

Beta-lactamases with improved properties for therapy Download PDF

Info

Publication number
AU2015247382B2
AU2015247382B2 AU2015247382A AU2015247382A AU2015247382B2 AU 2015247382 B2 AU2015247382 B2 AU 2015247382B2 AU 2015247382 A AU2015247382 A AU 2015247382A AU 2015247382 A AU2015247382 A AU 2015247382A AU 2015247382 B2 AU2015247382 B2 AU 2015247382B2
Authority
AU
Australia
Prior art keywords
beta
lactamase
mutation
polar
ambler classification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015247382A
Other languages
English (en)
Other versions
AU2015247382A1 (en
Inventor
Sheila Connelly
Michael Kaleko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theriva Biologics Inc
Original Assignee
Theriva Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theriva Biologics Inc filed Critical Theriva Biologics Inc
Publication of AU2015247382A1 publication Critical patent/AU2015247382A1/en
Application granted granted Critical
Publication of AU2015247382B2 publication Critical patent/AU2015247382B2/en
Assigned to THERIVA BIOLOGICS, INC. reassignment THERIVA BIOLOGICS, INC. Request to Amend Deed and Register Assignors: SYNTHETIC BIOLOGICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006Beta-lactamase (3.5.2.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2015247382A 2014-04-17 2015-04-17 Beta-lactamases with improved properties for therapy Active AU2015247382B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461980844P 2014-04-17 2014-04-17
US61/980,844 2014-04-17
US201462046627P 2014-09-05 2014-09-05
US62/046,627 2014-09-05
PCT/US2015/026457 WO2015161243A2 (en) 2014-04-17 2015-04-17 Beta-lactamases with improved properties for therapy

Publications (2)

Publication Number Publication Date
AU2015247382A1 AU2015247382A1 (en) 2016-09-15
AU2015247382B2 true AU2015247382B2 (en) 2020-04-23

Family

ID=54321063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015247382A Active AU2015247382B2 (en) 2014-04-17 2015-04-17 Beta-lactamases with improved properties for therapy

Country Status (10)

Country Link
US (14) US9290754B2 (US06650917-20031118-M00005.png)
EP (1) EP3132033B1 (US06650917-20031118-M00005.png)
JP (2) JP6685925B2 (US06650917-20031118-M00005.png)
KR (1) KR102360582B1 (US06650917-20031118-M00005.png)
CN (1) CN106163546B (US06650917-20031118-M00005.png)
AU (1) AU2015247382B2 (US06650917-20031118-M00005.png)
BR (1) BR112016023360B1 (US06650917-20031118-M00005.png)
CA (1) CA2942971C (US06650917-20031118-M00005.png)
RU (1) RU2678124C2 (US06650917-20031118-M00005.png)
WO (1) WO2015161243A2 (US06650917-20031118-M00005.png)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330937B2 (en) 2014-10-08 2021-07-15 Theriva Biologics, Inc. Beta-lactamase formulations and uses thereof
WO2016144856A1 (en) * 2015-03-06 2016-09-15 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
WO2017144495A1 (en) * 2016-02-23 2017-08-31 Da Volterra Beta-lactamase variants
US10982205B2 (en) 2016-02-23 2021-04-20 Da Volterra Beta-lactamase variants
WO2018005606A1 (en) 2016-06-28 2018-01-04 Synthetic Biologics, Inc. Microbiome protection from oral antibiotics
KR20210040395A (ko) 2018-08-05 2021-04-13 다 볼떼라 이식편 대 숙주 질환의 치료를 위한 조성물
AU2019317986A1 (en) 2018-08-05 2021-02-11 Da Volterra Method for improving anticancer agent efficacy
CN109337889B (zh) * 2018-12-26 2020-10-02 广州白云山拜迪生物医药有限公司 一种酶活提高的金属β-内酰胺酶突变体及其构建方法
CN109576250A (zh) * 2018-12-26 2019-04-05 广州白云山拜迪生物医药有限公司 一种酶活提高的头孢菌素酶突变体及其构建方法
CN113939308A (zh) * 2019-05-06 2022-01-14 合成生物制品有限公司 用于治疗移植物抗宿主病的β-内酰胺酶组合物
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes
WO2024012487A1 (en) * 2022-07-14 2024-01-18 The Hong Kong Polytechnic University Biosensor comprising a modified beta-lactamase and uses thereof
CN115433701B (zh) * 2022-11-08 2023-03-17 南京农业大学 一株变形杆菌及其菌剂和在降解头孢类抗生素中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004032995A1 (de) * 2004-07-08 2006-03-30 Henkel Kgaa Neue, sekretierte Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren
WO2008066931A2 (en) * 2006-11-29 2008-06-05 Novozymes, Inc. Bacillus licheniformis chromosome
WO2011148041A1 (en) * 2010-05-24 2011-12-01 Prevab R Llc Modified beta-lactamases and methods and uses related thereto
US8168417B2 (en) * 2004-01-09 2012-05-01 Novozymes A/S Bacillus licheniformis chromosome

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL197650A (US06650917-20031118-M00005.png) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
JPH11509096A (ja) 1995-07-07 1999-08-17 ノボ ノルディスク アクティーゼルスカブ 胞子形成できないバチルスを用いるタンパク質の生産
CN1363680A (zh) * 2001-01-05 2002-08-14 上海博德基因开发有限公司 一种新的多肽——β内酰胺酶20.24和编码这种多肽的多核苷酸
EP1391502B1 (en) 2001-05-29 2012-04-25 Kao Corporation Host microorganisms
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
AU2006249100B2 (en) 2005-05-18 2012-01-19 Assistance Publique - Hospitaux De Paris Colonic delivery of adsorbents
FI119190B (fi) * 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
CN101104858A (zh) * 2006-07-10 2008-01-16 温州医学院 一种体外定向进化获取高活力超广谱β-内酰胺酶的方法
FI119678B (fi) 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
CN101647022B (zh) * 2007-01-31 2012-07-18 麦科罗医药科技(武汉)有限公司 描述蛋白质的构象和根据折叠、整体形状与结构序列对其进行评价的方法、系统及装置
US9458453B2 (en) * 2012-06-12 2016-10-04 The Johns Hopkins University Methods for efficient, expansive, user-defined DNA mutagenesis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168417B2 (en) * 2004-01-09 2012-05-01 Novozymes A/S Bacillus licheniformis chromosome
DE102004032995A1 (de) * 2004-07-08 2006-03-30 Henkel Kgaa Neue, sekretierte Genprodukte von Bacillus licheniformis und darauf aufbauende verbesserte biotechnologische Produktionsverfahren
WO2008066931A2 (en) * 2006-11-29 2008-06-05 Novozymes, Inc. Bacillus licheniformis chromosome
WO2011148041A1 (en) * 2010-05-24 2011-12-01 Prevab R Llc Modified beta-lactamases and methods and uses related thereto

Also Published As

Publication number Publication date
US10011824B2 (en) 2018-07-03
BR112016023360A2 (US06650917-20031118-M00005.png) 2017-08-15
US9376673B1 (en) 2016-06-28
US20170314006A1 (en) 2017-11-02
US20160362674A1 (en) 2016-12-15
WO2015161243A3 (en) 2016-02-11
JP2020054368A (ja) 2020-04-09
US20200347375A1 (en) 2020-11-05
KR102360582B1 (ko) 2022-02-08
US9404103B1 (en) 2016-08-02
US9464280B1 (en) 2016-10-11
US20220098566A1 (en) 2022-03-31
JP2017515466A (ja) 2017-06-15
US20200157521A1 (en) 2020-05-21
US20230313166A1 (en) 2023-10-05
US10087433B1 (en) 2018-10-02
US20180023072A1 (en) 2018-01-25
RU2016140627A3 (US06650917-20031118-M00005.png) 2018-11-29
US20200017844A1 (en) 2020-01-16
CA2942971C (en) 2023-03-14
US20160303207A1 (en) 2016-10-20
US11236319B2 (en) 2022-02-01
CN106163546A (zh) 2016-11-23
KR20160144996A (ko) 2016-12-19
EP3132033A4 (en) 2017-11-29
US11608494B2 (en) 2023-03-21
RU2016140627A (ru) 2018-05-17
US9783797B1 (en) 2017-10-10
JP7038094B2 (ja) 2022-03-17
AU2015247382A1 (en) 2016-09-15
WO2015161243A2 (en) 2015-10-22
US20180305678A1 (en) 2018-10-25
US20180362954A1 (en) 2018-12-20
US10336995B2 (en) 2019-07-02
US9290754B2 (en) 2016-03-22
CN106163546B (zh) 2021-02-19
US9695409B2 (en) 2017-07-04
EP3132033A2 (en) 2017-02-22
RU2678124C2 (ru) 2019-01-23
US10584326B2 (en) 2020-03-10
EP3132033B1 (en) 2019-10-30
BR112016023360B1 (pt) 2023-03-07
JP6685925B2 (ja) 2020-04-22
US10767171B2 (en) 2020-09-08
US20150297689A1 (en) 2015-10-22
CA2942971A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
US11608494B2 (en) Beta-lactamases with improved properties for therapy
Bahr et al. Metallo-β-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design
EP3261662B1 (en) Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
EP2486131A1 (en) Carbapenemase and antibacterial treatment
Fontana et al. The final goal: penicillin-binding proteins and the target of cephalosporins
Cheng Structural and functional studies of antibiotic resistance enzymes
Medina Active Site Loops and Substrate Profile in Class B Metallo-β-Lactamases: From Mechanistic Studies to Therapy Development

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: THERIVA BIOLOGICS, INC.

Free format text: FORMER NAME(S): SYNTHETIC BIOLOGICS, INC.